Teva jams down pricing on €4bn M&A trade, as investors post jumbo orders
Mirko Popadic/yossarian6 - Fotolia
Israeli-American pharmaceutical company Teva made a swift entry into the European investment grade corporate bond market on Wednesday, winning an order book to rival AB-InBev’s €13.25bn record breaker.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: